查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844190

生物医学植入市场：整形外科植入、心血管植入、人工植牙、脊椎移植、神经植入、眼科植入－2025-2032年全球预测

Biological Implants Market by Orthopedic Implants, Cardiovascular Implants, Dental Implants, Spinal Implants, Neurological Implants, Ocular Implants - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，生物医学植入市场规模将达到 2,003.9 亿美元，复合年增长率为 21.97%。

关键市场统计数据
基准年 2024 409亿美元
预计年份：2025年 499.1亿美元
预测年份 2032 2003.9亿美元
复合年增长率 (%) 21.97%

目前生物植入的格局由临床、技术和操作驱动因素构成，这些因素决定了其普及率和长期生存能力。

生物植入领域融合了先进材料科学、外科创新和不断发展的法律规范，为医疗保健相关人员带来了机会和挑战。生物材料、微型电子装置和植入式药物输送技术的快速发展正在拓展治疗范围，同时也引发了人们对长期疗效、生物相容性和临床证据生成等方面的疑问。在临床上，包括整形外科、心血管科、牙科、神经科、眼科和脊椎医学在内的多学科团队正在重新定义治疗流程，这需要整合产品策略，以兼顾手术流程、患者报告结果和支付方动态。

在营运方面，製造商和供应商正面临供应链预期提高、上市后监管更加严格以及对连网型设备网路安全要求日益增长的挑战。技术融合——即感测器、人工智慧驱动的诊断和自适应刺激与现有植入平台的结合——将加速创新步伐，但也需要更深入的跨职能协作。随着早期采用者展现出临床和经济价值，采购、临床和监管领域的相关人员必须通力合作，将设备层面的进步转化为可扩展的治疗路径，优先考虑安全性、报销可行性和患者公平获取治疗的机会。

个人化、数位增强、流程创新和日益严格的监管如何重塑产品开发、临床应用和供应策略

植入式医疗技术领域正经历变革时期是由科技、临床和政策三方力量的融合所驱动的。首先，随着材料科学和製造技术的进步，个人化正从概念走向实践，这使得针对特异性患者个体差异和不断变化的疾病特征的植入和模组化平台成为可能。其次，微创和影像导引手术正在拓展适应症范围并缩短恢復时间，从而将价值评估的重点从单纯的器械成本转移到全面的治疗效果。第三，透过植入式感测器、远端监测和预测分析等数位化手段，可以实现持续的性能评估和早期干预，从而将上市后监管从例行检查转变为即时管理。

同时，法律规范也在调整以适应这些变化，更加强调强有力的临床证据、生命週期管理以及网路设备的网路安全控制。供应商和製造商正在努力平衡全球化与在地化能力的需求，以确保关键组件的持续供应。这种转变也影响着投资重点，资本越来越倾向于可互通的生态系统、模组化升级以及能够显着改善以患者为中心的治疗效果的平台。因此，那些能够将临床洞察力、监管前瞻性和製造灵活性相结合的机构，将更有利于赢得临床信任和提升营运韧性。

评估2025年美国关税对零件采购、生产布局和采购行为的营运和策略影响

美国关税政策将于2025年生效，这将为植入医疗器材製造商、供应商和经销商带来复杂的挑战，影响直接采购成本和更广泛的供应链决策。在零件层面，对某些进口原料征收的关税加剧了依赖海外特种合金、电子元件和成品模组的医疗器材的价格压力。为此，许多供应商已启动快速成本透明化计划，并重新谈判供货条款，以保护净利率并维持临床应用。同时，一些製造商加快了寻找替代供应商或增加关键零件的在地采购，以降低贸易政策波动的风险。

除了直接的成本影响外，关税政策也影响了企业在製造地和库存配置方面的策略选择。一些公司重新审视了其在地化策略，并评估了在近岸或境内生产方面的投资，以降低未来的政策风险并缩短补货前置作业时间。此类投资通常需要对品质系统、监管申报、员工培训等方面进行相应的调整，这会带来短期实施挑战，但从长远来看可以提高营运韧性。临床医生和采购团队观察到，价格动态促使企业进行更严格的评估并延长合约谈判时间，从而加强了临床证据团队和商业部门之间的合作，以确保在维持永续经营模式的同时，保障患者的用药可及性。

細項分析突显了从整形外科到眼科器械等不同植入子类别如何需要独特的开发、监管和商业化策略。

对植入类别进行细緻的细分，揭示了不同的创新路径、监管考虑和临床应用模式，这些都需要针对产品开发和商业化製定量身定制的策略。整形外科植入类别包括关节关节重建、骨合成和创伤固定。关节置换又细分为髋置换术、膝关节关节重建和肩关节关节重建，每种置换方式都有其独特的手术流程和植入生命週期考量。关节重建分为骨板和骨螺钉，而创伤固定则涵盖外固定器、髓内钉以及钢板和螺丝。每个子类别都有特定的材料和机械性能要求，这些要求会影响研发重点。

心血管植入包括心臟瓣膜、支架和血管假体。心臟瓣膜分为机械瓣膜和生物膜瓣膜，支架分为裸金属支架和药物释放型，二者监管途径和预期证据各不相同。人工植牙分为骨内植入、骨膜下植入和颧骨植入。骨内植入又分为刀片型和根型，分别针对不同的解剖结构限制和修復概念。脊椎移植植入椎间盘植入、脊椎融合手术和脊椎固定器。脊椎融合手术进一步分为钢板、螺丝和棒状融合器，脊椎固定器包括骨全人工椎间盘置换术和椎间融合器，展现出不同的生物整合方式和装置-宿主相互作用。神经系统植入包括深层脑部刺激器、脊髓刺激设备和迷走神经刺激设备。深层脑部刺激器分为自适应型和固定型，脊髓刺激设备分为桨状型和经皮型，这反映了精准医疗和植入物复杂性的差异。眼部植入主要包括人工水晶体和视网膜植入。人工人工水晶体分为单焦点、多焦点和散光型，视网膜植入分为视网膜上植入和视网膜下植入，每种植入方式都需要特定的手术技术和患者选择标准。

了解这些细分领域的细微差别有助于制定量身定制的临床开发计划和有针对性的报销策略。例如，模组化平台和升级路径更适用于关节重建和脊椎系统，而小型化和电源管理在神经和视网膜植入中发挥核心作用。监管申报策略、上市后证据产生和临床医生培训计划必须与每个细分节点的独特机械、生物学和手术特性相匹配。

主要全球区域间不同的管理体制、报销框架和产能投资将如何影响临床应用和商业化选择

区域动态持续影响着製造商和医疗保健系统的优先事项，不同地域市场在监管、报销和临床应用方面呈现出显着差异。在美洲，临床机构高度重视实证创新和流程效率，而支付者也越来越倾向于根据可验证的疗效和真实世界绩效指标进行报销。在该地区运营的製造商正优先投资于完善的上市后监测系统、与整合医疗服务网络建立合作关係以及开展临床医生培训，以支持在成本敏感的环境下推广应用。

在欧洲、中东和非洲，监管协调和跨境核准正在影响产品上市时间和临床试验设计，而多样化的支付模式则要求企业制定灵活的定价和准入策略。该地区还存在集中采购项目和高度分散的医院采购并存的现象，这要求製造商在标准化的价值文件和区域价值声明之间取得平衡。在亚太地区，科技的快速普及以及监管成熟度的差异，促使企业更加关注可扩展的生产和成本竞争力。该地区的多个市场正在大力投资建立本土能力并产生本地临床证据，这既为寻求建立永续的、与当地实际情况相关的供应和证据策略的全球企业创造了合作机会，也带来了竞争压力。

在竞争动态中，跨国公司的规模优势与新兴企业专注的创新能力相互融合，共同推动伙伴关係、平台策略和有针对性的临床差异化发展。

植入医疗器材领域的竞争格局涵盖了从成熟的跨国医疗器材製造商到敏捷的临床阶段新兴企业，形成了一个充满活力的环境，规模、监管专业知识和专注的创新都至关重要。领先企业利用其广泛的产品系列、深厚的临床网络和完善的品质系统来支援复杂的销售週期和全球监管申报。这些企业优先考虑生命週期管理、模组化平台策略以及旨在拓展临床适应症和整合数位医疗能力的策略伙伴关係。

同时，规模较小的专业公司和学术衍生企业正在材料、感测和自适应刺激领域取得突破性进展，往往能在特定适应症领域获得先发优势。这些创新者通常会追求有针对性的临床概念验证，并达成策略性的合作开发和授权协议，以加速产品进入市场。投资者和企业发展团队正致力于建立能够互补核心优势的合作伙伴关係，例如将先进的生物材料与成熟的手术器械相结合，或在成熟的植入平台中添加软体分析功能，以缩短临床应用时间，并扩大其对医疗服务提供者和患者的价值范围。在竞争激烈的市场中，那些能够协调监管策略、证据生成和商业性拓展的企业将能够保持其差异化优势和赢得患者的信任。

企业应采取切实可行的策略和营运步骤，以增强韧性、加速临床应用并确保与监管机构和支付方保持一致。

产业领导者必须将洞察转化为可执行的步骤，以增强韧性、加速产品推广应用、保障病人安全并维持商业性可行性。首先，绘製关键供应链节点图，并对高风险组件的二级供应商进行资格认证。同时，实施透明的成本和前置作业时间管治，以降低政策变化和物流中断带来的风险。其次，透过设计务实的试验和真实世界证据项目，投资产生符合支付方终点的临床证据，以证明功能性结果、再入院率和设备长期性能的改善。第三，在产品设计中优先考虑模组化和可升级性，以延长临床有效性并实现迭代改进，而无需彻底更换。

此外，我们将从设备开发的早期设计阶段融入网路安全和软体生命週期管理，并在允许的情况下，利用远端监测数据，建立清晰的上市后监测路径。我们将透过与医疗系统建立策略合作伙伴关係，并实施共同开发的价值路径和医护人员教育计划，来加速手术流程的推广应用。最后，我们将培养政策参与和监管情报能力，透过预测合规性变化并使开发时间表与不断变化的核准要求保持一致，来减少市场准入和扩张过程中的阻力。

我们采用综合研究途径，结合临床、监管、供应链和专家意见，以确保获得全面且检验的研究结果。

本分析所依据的研究结合了对监管文件、同行评审的临床文献、专利和公共器械註册资讯的系统性回顾，以及来自临床医生、采购负责人、监管专家和生产企业高管的专家意见。主要研究包括对多个专科的执业外科医生、医疗设备公司的品质和监管负责人以及负责植入物物流的供应链经理进行结构化访谈和研讨会。次要研究包括对临床试验註册资讯、监管机构发布的指导文件以及特定医疗设备的上市后监测摘要的分析，以全面了解安全性和性能趋势。

透过交叉比对临床结果、设备技术规格和监管路径，对数据进行三角验证，以检验主题研究结果。调查方法的局限性包括不同地区公开资料的完整性存在差异，以及与某些供应商签订的合约可能具有排他性，这可能会限制对特定成本结构的了解。为了弥补这些观察，当直接证据有限时，采用了定性加权法；所有原始数据均已匿名化，并获得了使用许可。整个研究过程均遵循伦理标准，强调分析方法的透明度和可重复性。

整合策略重点，将设备创新、证据产生和营运韧性连结起来，以实现持续的临床和系统层面的效益。

生物植入正进入一个技术多样性和系统层面考量将决定最终产品优胜者和患者获益的关键阶段。个人化材料、数位化监测和手术创新的融合正在重塑价值体系，使其从以设备为中心的特性转向整合式医疗服务。能够协调平台设计、临床证据策略和自适应製造的机构，不仅能够更有效地应对当前的政策和采购压力，还能透过显着改善患者功能和提升医疗效率，为生物植入物的永续应用开闢新途径。

展望未来，产业界、临床实践和政策制定者之间的合作必须致力于建立互通的生态系统、透明的上市后证据框架以及灵活的监管互动，从而将医疗器材创新与可衡量的临床效益联繫起来。本摘要中阐述的策略重点——供应链韧性、有针对性的证据产生和平台模组化——为寻求将创新与现实世界的临床和营运需求相契合的领导者提供了切实可行的蓝图。持续关注以患者为中心的治疗结果和负责任的技术管理，对于维护社会信任和确保植入式技术带来持久的健康益处至关重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 生物可吸收心血管支架的创新技术可实现标靶药物传递和血管修復
  • 开发用于治疗神经退化性疾病的自适应深部脑部刺激神经介面植入
  • 用于骨整合的具有多孔生物相容性晶格结构的3D列印客製化整形外科植入的研究进展
  • 智慧血糖监测植入整合了连续遥测数据和预测性胰岛素剂量演算法
  • 人工电子耳可改善神经组织整合和讯号保真度
  • 在人工植牙表面植入免疫调节涂层，以降低植体周围炎的风险。
  • 基于先进成像和动态建模的AI驱动型患者特异性颅骨植入设计优化
  • 用于脊椎固定移植植入的干细胞接种水凝胶支架可促进骨形成并缩短恢復时间
  • 用于新一代心臟起搏器植入的无线电力传输解决方案可延长植入寿命并实现远端充电。
  • 生物可降解的硅基神经感测器可在体内提供即时电生理监测和数据分析。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 生物医学植入市场－整形外科植入

  • 关节重建
    • 髋关节置换术
    • 膝关节关节重建
    • 关节重建
  • 骨合成
    • 骨板
    • 骨螺丝
  • 创伤固定
    • 外固定装置
    • 髓内钉
    • 板材和螺丝

第九章 生物医学植入市场：心血管植入

  • 心臟瓣膜
    • 机器
    • 组织
  • 支架
    • 裸金属
    • 药物释放型
  • 血管移植

第十章：人工植牙植入

  • 骨内植入
    • 刀刃形态
    • 字根形式
  • 骨膜下植入
  • 颧骨植入

第十一章 生医植入市场－脊椎移植

  • 全人工椎间盘置换术
  • 脊椎融合
    • 盘子
    • 螺丝和桿
  • 脊椎固定器
    • 移植骨替代物
    • 笼

第十二章：生物植入市场－神经植入

  • 深层脑部刺激器
    • 自适应
    • 固定利率
  • 脊髓刺激设备
    • 桨
    • 经皮
  • 迷走神经刺激设备

第十三章植入市场：眼内植入

  • 人工水晶体
    • 单焦点
    • 多焦点
    • 托里卡
  • 视网膜植入
    • 视网膜前膜
    • 视网膜下

第十四章 生物医学植入市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 生物医学植入市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国生物医学植入市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Johnson & Johnson
    • Medtronic plc
    • Stryker Corporation
    • Zimmer Biomet Holdings, Inc.
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Edwards Lifesciences Corporation
    • Smith & Nephew plc
    • Becton, Dickinson and Company
    • Globus Medical, Inc.
Product Code: MRR-ED54C46E8D5E

The Biological Implants Market is projected to grow by USD 200.39 billion at a CAGR of 21.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 40.90 billion
Estimated Year [2025] USD 49.91 billion
Forecast Year [2032] USD 200.39 billion
CAGR (%) 21.97%

Framing the contemporary biological implants landscape with clinical, technological, and operational drivers that determine adoption and long-term viability

The field of biological implants sits at the intersection of advanced materials science, surgical innovation, and evolving regulatory oversight, creating both opportunity and complexity for healthcare stakeholders. Rapid advances in biomaterials, miniaturized electronics, and implantable drug delivery are extending therapeutic reach while simultaneously raising questions around long-term performance, biocompatibility, and clinical evidence generation. At the clinical interface, multidisciplinary teams are redefining treatment algorithms across orthopedics, cardiovascular care, dentistry, neurology, ophthalmology, and spinal medicine, demanding integrated product strategies that account for procedural workflow, patient-reported outcomes, and payer dynamics.

Operationally, manufacturers and providers are navigating tighter supply chain expectations, heightened scrutiny over post-market surveillance, and rising expectations for cybersecurity in connected devices. Technological convergence-where sensors, AI-driven diagnostics, and adaptive stimulation meet established implant platforms-is accelerating the pace of innovation but also requiring deeper cross-functional collaboration. As early adopters demonstrate clinical and economic value, procurement, clinical, and regulatory stakeholders must coordinate to translate device-level advances into scalable care pathways that prioritize safety, reimbursement viability, and equitable patient access.

How personalization, digital augmentation, procedural innovation, and regulatory tightening are reshaping product development, clinical adoption, and supply strategies

The landscape for implantable medical technologies is undergoing transformative shifts driven by converging technological, clinical, and policy forces. First, personalization is moving from concept to practice as materials science and manufacturing advances enable patient-specific implants and modular platforms that accommodate anatomical variability and evolving disease presentations. Second, minimally invasive and image-guided procedures are expanding indications and shortening recovery times, shifting value conversations from device cost alone to total episode-of-care outcomes. Third, digital augmentation-through sensors embedded in implants, remote monitoring, and predictive analytics-enables continuous performance assessment and earlier interventions, thereby reframing post-market surveillance from periodic checks to real-time stewardship.

In parallel, regulatory frameworks are adapting to these changes by emphasizing robust clinical evidence, lifecycle management, and cybersecurity controls for networked devices. Supply chains are also recalibrating; providers and manufacturers are balancing globalization with the need for onshore capabilities to ensure continuity of critical components. These shifts are influencing investment priorities, where capital increasingly favors platforms that offer interoperable ecosystems, modular upgrades, and demonstrable improvements in patient-centered outcomes. Consequently, organizations that integrate clinical insight, regulatory foresight, and manufacturing flexibility will be best positioned to capture clinical trust and operational resilience.

Assessing the operational and strategic consequences of the 2025 United States tariff measures on component sourcing, manufacturing footprints, and procurement behaviors

The tariff environment in the United States introduced in 2025 has created a complex set of considerations for manufacturers, providers, and distributors of implantable devices, affecting both direct procurement costs and broader supply chain decisions. At the component level, duties on certain imported inputs have increased the price pressure for devices that rely on specialized alloys, electronic components, and finished modules sourced overseas. In response, many suppliers initiated rapid cost-transparency programs and renegotiated supplier terms to protect margin and preserve clinical access. Simultaneously, some manufacturers accelerated qualifications of alternative suppliers and increased local sourcing for critical components to reduce exposure to trade policy volatility.

Beyond direct cost impacts, the tariff stance influenced strategic choices around manufacturing footprint and inventory posture. Several organizations revisited localization strategies, evaluating near-shore and onshore manufacturing investments to mitigate future policy risk and shorten replenishment lead times. These investments often required parallel adjustments to quality systems, regulatory filings, and workforce training, creating near-term implementation challenges but improving operational resilience long term. Clinicians and procurement teams observed that pricing dynamics prompted more stringent value assessments and extended contract negotiations, encouraging stronger collaboration between clinical evidence teams and commercial functions to preserve access while maintaining sustainable business models.

Segment-specific analysis highlighting how implant subcategories from orthopedics to ocular devices demand distinct development, regulatory, and commercialization strategies

A nuanced segmentation of implant classes reveals differentiated innovation pathways, regulatory considerations, and clinical adoption patterns that demand tailored strategies for product development and commercialization. The orthopedic implant category encompasses joint replacement, osteosynthesis, and trauma fixation; joint replacement further differentiates into hip, knee, and shoulder replacement subdomains, each with distinct surgical workflows and implant lifecycle considerations. Osteosynthesis divides into bone plates and bone screws, while trauma fixation spans external fixators, intramedullary nails, and plates and screws, with each subcategory exhibiting specific material and mechanical performance requirements that influence R&D priorities.

Cardiovascular implants include heart valves, stents, and vascular grafts; heart valves are split between mechanical and tissue options, and stents are categorized as bare metal or drug-eluting, with divergent regulatory paths and evidence expectations. Dental implants are reviewed across endosseous, subperiosteal, and zygomatic implants; endosseous implants further separate into blade form and root form, each addressing different anatomical constraints and restoration philosophies. Spinal implants cover disc replacement, spinal fixation, and spinal fusion devices; spinal fixation is further detailed as plates and screws and rods, while spinal fusion devices include bone graft substitutes and cages, signaling varied biological integration and device-host interactions. Neurological implants span deep brain stimulators, spinal cord stimulators, and vagal nerve stimulators; deep brain stimulators are examined in adaptive and fixed-rate formats, and spinal cord stimulators in paddle and percutaneous configurations, reflecting differences in precision therapy and implantation complexity. Ocular implants concentrate on intraocular lenses and retinal implants; intraocular lenses are profiled as monofocal, multifocal, and toric, and retinal implants as epiretinal and subretinal, each demanding specialized surgical techniques and patient selection criteria.

Understanding these segment-specific nuances enables tailored clinical development plans and targeted reimbursement strategies. For example, modular platforms and upgrade paths are more relevant in joint replacement and spinal systems, whereas miniaturization and power management are central to neurological and retinal implants. Regulatory submission strategies, post-market evidence generation, and clinician training programs must align with the mechanical, biological, and procedural characteristics unique to each segmentation node to optimize adoption and long-term safety outcomes.

How divergent regulatory regimes, reimbursement frameworks, and capacity investments across major global regions influence clinical adoption and commercialization choices

Regional dynamics continue to drive differentiated priorities for manufacturers and health systems, with geographic markets exhibiting distinct regulatory, reimbursement, and clinical adoption patterns. In the Americas, clinical practice strongly favors evidence-backed innovations and procedural efficiency, and payers increasingly condition reimbursement on demonstrable outcomes and real-world performance metrics. Manufacturers operating in this region prioritize robust post-market surveillance systems, partnerships with integrated delivery networks, and investments in clinician education to support uptake in cost-conscious environments.

Across Europe, Middle East & Africa, regulatory harmonization and cross-border approvals influence go-to-market sequencing and clinical trial design, while diverse payer models require adaptable pricing and access strategies. The region presents a mixture of centralized procurement programs in some jurisdictions and highly decentralized hospital purchasing in others, so manufacturers must balance standardized value dossiers with localized value arguments. In the Asia-Pacific region, rapid technology adoption is coupled with varied regulatory maturity and an emphasis on scalable manufacturing and cost competitiveness. Several markets in this region are investing heavily in domestic capacity building and local clinical evidence generation, which creates both collaboration opportunities and competitive pressures for global firms that seek to establish sustainable, regionally relevant supply and evidence strategies.

Competitive dynamics where multinational scale and focused startup innovation converge, driving partnerships, platform strategies, and targeted clinical differentiation

The competitive landscape for implant technologies reflects a spectrum from established multinational device manufacturers to agile clinical-stage startups, creating a dynamic environment where scale, regulatory expertise, and focused innovation all matter. Large corporate players continue to leverage broad product portfolios, deep clinical networks, and extensive quality systems to support complex sales cycles and global regulatory submissions. These firms prioritize lifecycle management, modular platform strategies, and strategic partnerships that expand clinical indications and integrate digital health capabilities.

At the same time, smaller specialized companies and academic spinouts are driving breakthroughs in materials, sensing, and adaptive stimulation, often securing first-mover clinical differentiation in narrow indications. These innovators typically pursue targeted clinical proof points and strategic co-development or licensing arrangements to accelerate market entry. Investors and corporate development teams are focusing on collaborations that complement core strengths-such as pairing advanced biomaterials with established surgical instruments or attaching software-enabled analytics to proven implant platforms-to reduce time to clinical adoption and expand the perimeter of value for providers and patients. Across the competitive set, organizations that synchronize regulatory strategy, evidence generation, and commercial engagement will sustain differentiation and patient trust.

Practical strategic and operational measures companies should implement to enhance resilience, accelerate clinical adoption, and secure regulatory and payer alignment

Industry leaders must translate insight into practical steps that bolster resilience, accelerate adoption, and protect patient safety while preserving commercial viability. First, map critical supply chain nodes and qualify secondary suppliers for high-risk components, while implementing transparent cost and lead-time governance to reduce exposure to policy shifts and logistical disruption. Second, invest in clinical evidence generation that aligns with payer endpoints by designing pragmatic trials and real-world evidence programs that demonstrate improvements in functional outcomes, readmissions, and longitudinal device performance. Third, prioritize modularity and upgradeability in product design to extend clinical relevance and enable iterative improvements without wholesale replacement.

Additionally, integrate cybersecurity and software lifecycle management into device development from the earliest design phases, and establish clear pathways for post-market surveillance that leverage remote monitoring data where permitted. Pursue strategic alliances with health systems for co-developed value pathways and provider education programs to accelerate procedural adoption. Finally, cultivate policy engagement and regulatory intelligence capabilities to anticipate compliance changes and to align development timelines with evolving approval requirements, thereby reducing friction in market entry and scaling.

Integrated research approach combining clinical, regulatory, supply chain, and expert practitioner inputs to ensure comprehensive and validated findings

The research underpinning this analysis combined systematic review of regulatory documentation, peer-reviewed clinical literature, patents, and public device registries with targeted expert input from clinicians, procurement leaders, regulatory specialists, and manufacturing executives. Primary engagements included structured interviews and workshops with practicing surgeons across multiple specialties, quality and regulatory leaders within medical device firms, and supply chain managers responsible for implant logistics. Secondary research encompassed analysis of clinical trial registries, guidance documents issued by regulatory authorities, and device-specific post-market surveillance summaries to ensure a comprehensive view of safety and performance trends.

Data were triangulated by cross-referencing clinical outcomes, device technical specifications, and regulatory pathways to validate thematic findings. Limitations of the methodology include variability in public data completeness across regions and the proprietary nature of certain supplier contracts, which can constrain visibility into specific cost structures. To mitigate these constraints, qualitative weighting was applied where direct evidence was limited, and all primary inputs were anonymized and consented for use. Ethical standards were observed throughout the research process, with an emphasis on transparency and reproducibility of the analytic approach.

Synthesis of strategic priorities that connect device innovation, evidence generation, and operational resilience to realize durable clinical and system-level benefits

Biological implants are entering a phase where technological plurality and system-level considerations determine winner profiles and patient impact. The confluence of personalized materials, digital monitoring, and procedural innovation is reshaping the value equation from device-centric attributes to integrated care outcomes. Organizations that harmonize platform design, clinical evidence strategies, and adaptive manufacturing will not only navigate current policy and procurement pressures more effectively but will also unlock new avenues for sustainable adoption through demonstrable improvements in patient function and care efficiency.

Looking ahead, collaborators across industry, clinical practice, and policy will need to invest in interoperable ecosystems, transparent post-market evidence frameworks, and agile regulatory engagement to translate device innovation into measurable clinical benefits. The strategic priorities articulated in this summary-supply chain resilience, targeted evidence generation, and platform modularity-provide a pragmatic blueprint for leaders seeking to align innovation with real-world clinical and operational demands. Continued focus on patient-centric outcomes and responsible technology stewardship will be essential to maintaining public trust and ensuring that implantable technologies deliver durable health gains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Innovations in bioresorbable cardiovascular stents enabling targeted drug delivery and vessel healing
  • 5.2. Development of neural interface implants for adaptive deep brain stimulation in neurodegenerative treatments
  • 5.3. Advances in 3D-printed custom orthopedic implants with porous biocompatible lattice structures for osseointegration
  • 5.4. Smart glucose monitoring implants integrating continuous telemetry data with predictive insulin delivery algorithms
  • 5.5. Genetically engineered bioactive coatings on cochlear implants for enhanced neural tissue integration and signal fidelity
  • 5.6. Implementation of immunomodulatory surface coatings in dental implants to mitigate peri-implantitis inflammation risks
  • 5.7. AI-driven design optimization of patient-specific cranial implants based on advanced imaging and biomechanical modeling
  • 5.8. Stem cell seeded hydrogel scaffolds in spinal fusion implants accelerating osteogenesis and reducing recovery times
  • 5.9. Wireless power transfer solutions for next generation cardiac pacemaker implants enabling longer implant lifespans and remote charging
  • 5.10. Biodegradable silicon based neural sensors providing real-time electrophysiological monitoring and data analytics in vivo

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biological Implants Market, by Orthopedic Implants

  • 8.1. Joint Replacement
    • 8.1.1. Hip Replacement
    • 8.1.2. Knee Replacement
    • 8.1.3. Shoulder Replacement
  • 8.2. Osteosynthesis
    • 8.2.1. Bone Plates
    • 8.2.2. Bone Screws
  • 8.3. Trauma Fixation
    • 8.3.1. External Fixators
    • 8.3.2. Intramedullary Nails
    • 8.3.3. Plates And Screws

9. Biological Implants Market, by Cardiovascular Implants

  • 9.1. Heart Valves
    • 9.1.1. Mechanical
    • 9.1.2. Tissue
  • 9.2. Stents
    • 9.2.1. Bare Metal
    • 9.2.2. Drug Eluting
  • 9.3. Vascular Grafts

10. Biological Implants Market, by Dental Implants

  • 10.1. Endosseous Implants
    • 10.1.1. Blade Form
    • 10.1.2. Root Form
  • 10.2. Subperiosteal Implants
  • 10.3. Zygomatic Implants

11. Biological Implants Market, by Spinal Implants

  • 11.1. Disc Replacement
  • 11.2. Spinal Fixation
    • 11.2.1. Plates
    • 11.2.2. Screws And Rods
  • 11.3. Spinal Fusion Devices
    • 11.3.1. Bone Graft Substitutes
    • 11.3.2. Cages

12. Biological Implants Market, by Neurological Implants

  • 12.1. Deep Brain Stimulators
    • 12.1.1. Adaptive
    • 12.1.2. Fixed Rate
  • 12.2. Spinal Cord Stimulators
    • 12.2.1. Paddle
    • 12.2.2. Percutaneous
  • 12.3. Vagal Nerve Stimulators

13. Biological Implants Market, by Ocular Implants

  • 13.1. Intraocular Lenses
    • 13.1.1. Monofocal
    • 13.1.2. Multifocal
    • 13.1.3. Toric
  • 13.2. Retinal Implants
    • 13.2.1. Epiretinal
    • 13.2.2. Subretinal

14. Biological Implants Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Biological Implants Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Biological Implants Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Johnson & Johnson
    • 17.3.2. Medtronic plc
    • 17.3.3. Stryker Corporation
    • 17.3.4. Zimmer Biomet Holdings, Inc.
    • 17.3.5. Abbott Laboratories
    • 17.3.6. Boston Scientific Corporation
    • 17.3.7. Edwards Lifesciences Corporation
    • 17.3.8. Smith & Nephew plc
    • 17.3.9. Becton, Dickinson and Company
    • 17.3.10. Globus Medical, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DENTAL IMPLANTS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DENTAL IMPLANTS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL IMPLANTS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL IMPLANTS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY NEUROLOGICAL IMPLANTS, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY NEUROLOGICAL IMPLANTS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY OCULAR IMPLANTS, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY OCULAR IMPLANTS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BIOLOGICAL IMPLANTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. BIOLOGICAL IMPLANTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOLOGICAL IMPLANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HIP REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HIP REPLACEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HIP REPLACEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HIP REPLACEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HIP REPLACEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HIP REPLACEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY KNEE REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY KNEE REPLACEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY KNEE REPLACEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY KNEE REPLACEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY KNEE REPLACEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY KNEE REPLACEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SHOULDER REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SHOULDER REPLACEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SHOULDER REPLACEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SHOULDER REPLACEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SHOULDER REPLACEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SHOULDER REPLACEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY OSTEOSYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY OSTEOSYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY OSTEOSYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY OSTEOSYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY OSTEOSYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY OSTEOSYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY OSTEOSYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY OSTEOSYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE PLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE PLATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE PLATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE PLATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE PLATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE PLATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE SCREWS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE SCREWS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE SCREWS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE SCREWS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE SCREWS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE SCREWS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY EXTERNAL FIXATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY EXTERNAL FIXATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY EXTERNAL FIXATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY EXTERNAL FIXATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY EXTERNAL FIXATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY EXTERNAL FIXATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY INTRAMEDULLARY NAILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY INTRAMEDULLARY NAILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY INTRAMEDULLARY NAILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY INTRAMEDULLARY NAILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY INTRAMEDULLARY NAILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY INTRAMEDULLARY NAILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PLATES AND SCREWS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PLATES AND SCREWS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PLATES AND SCREWS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PLATES AND SCREWS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PLATES AND SCREWS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PLATES AND SCREWS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HEART VALVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HEART VALVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HEART VALVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HEART VALVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HEART VALVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HEART VALVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MECHANICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MECHANICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MECHANICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MECHANICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MECHANICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MECHANICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BARE METAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BARE METAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BARE METAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BARE METAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BARE METAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BARE METAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DRUG ELUTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DRUG ELUTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DRUG ELUTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DRUG ELUTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DRUG ELUTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DRUG ELUTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DENTAL IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DENTAL IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ENDOSSEOUS IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ENDOSSEOUS IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ENDOSSEOUS IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ENDOSSEOUS IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ENDOSSEOUS IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ENDOSSEOUS IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ENDOSSEOUS IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ENDOSSEOUS IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BLADE FORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BLADE FORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BLADE FORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BLADE FORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BLADE FORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BLADE FORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ROOT FORM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ROOT FORM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ROOT FORM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ROOT FORM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ROOT FORM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ROOT FORM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBPERIOSTEAL IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBPERIOSTEAL IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBPERIOSTEAL IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBPERIOSTEAL IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBPERIOSTEAL IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBPERIOSTEAL IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ZYGOMATIC IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ZYGOMATIC IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ZYGOMATIC IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ZYGOMATIC IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ZYGOMATIC IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ZYGOMATIC IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DISC REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DISC REPLACEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DISC REPLACEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DISC REPLACEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DISC REPLACEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DISC REPLACEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FIXATION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FIXATION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FIXATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FIXATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FIXATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FIXATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FIXATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FIXATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PLATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PLATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PLATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PLATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PLATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SCREWS AND RODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SCREWS AND RODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SCREWS AND RODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SCREWS AND RODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SCREWS AND RODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SCREWS AND RODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FUSION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FUSION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FUSION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FUSION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FUSION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FUSION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FUSION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL FUSION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE GRAFT SUBSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE GRAFT SUBSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE GRAFT SUBSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE GRAFT SUBSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE GRAFT SUBSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY BONE GRAFT SUBSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CAGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CAGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY NEUROLOGICAL IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY NEUROLOGICAL IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DEEP BRAIN STIMULATORS, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DEEP BRAIN STIMULATORS, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DEEP BRAIN STIMULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DEEP BRAIN STIMULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DEEP BRAIN STIMULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DEEP BRAIN STIMULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DEEP BRAIN STIMULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DEEP BRAIN STIMULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ADAPTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ADAPTIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ADAPTIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ADAPTIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ADAPTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ADAPTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY FIXED RATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY FIXED RATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY FIXED RATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY FIXED RATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY FIXED RATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY FIXED RATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL CORD STIMULATORS, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL CORD STIMULATORS, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL CORD STIMULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL CORD STIMULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL CORD STIMULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL CORD STIMULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL CORD STIMULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SPINAL CORD STIMULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PADDLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PADDLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PADDLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PADDLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PADDLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PADDLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PERCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PERCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PERCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PERCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PERCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY PERCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY VAGAL NERVE STIMULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY VAGAL NERVE STIMULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY VAGAL NERVE STIMULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY VAGAL NERVE STIMULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY VAGAL NERVE STIMULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY VAGAL NERVE STIMULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY OCULAR IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY OCULAR IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY INTRAOCULAR LENSES, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY INTRAOCULAR LENSES, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY INTRAOCULAR LENSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY INTRAOCULAR LENSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY INTRAOCULAR LENSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY INTRAOCULAR LENSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY INTRAOCULAR LENSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY INTRAOCULAR LENSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MONOFOCAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MONOFOCAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MONOFOCAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MONOFOCAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MONOFOCAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MONOFOCAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MULTIFOCAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MULTIFOCAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MULTIFOCAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MULTIFOCAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MULTIFOCAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MULTIFOCAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TORIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TORIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TORIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TORIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TORIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TORIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY RETINAL IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY RETINAL IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY RETINAL IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY RETINAL IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY RETINAL IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY RETINAL IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY RETINAL IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY RETINAL IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY EPIRETINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY EPIRETINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY EPIRETINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY EPIRETINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY EPIRETINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY EPIRETINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBRETINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBRETINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBRETINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBRETINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBRETINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBRETINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY JOINT REPLACEMENT, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY OSTEOSYNTHESIS, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY OSTEOSYNTHESIS, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY TRAUMA FIXATION, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY HEART VALVES, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS